Evidence map›Paper›PMID 31527062›Full record

ReviewDevelopment (Cambridge, England)2019

Hippo signalling during development.

John Robert Davis, Nicolas Tapon

Open access · hybridAbstract readReview
In one paragraph

Review in Development (Cambridge, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 115 citations in OpenAlex.

  1. Comparing YAPBiomolecules · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The Roles of ProteinCancer communications (London, England) · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Hippo signaling in mammalian reproduction.Reproduction (Cambridge, England) · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

John Robert DavisApoptosis and Proliferation Control Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.ORCID 0000-0002-6022-0369
Nicolas TaponApoptosis and Proliferation Control Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK nic.tapon@crick.ac.uk.ORCID 0000-0001-5267-6510
The Francis Crick Institute · GB

Funding

Cancer Research UK 17064Wellcome Trust 107885Wellcome Trust 201358Wellcome Trust 201358/Z/16/ZWellcome Trust FC001175
6 · The paper itself

Abstract

The Hippo signalling pathway and its transcriptional co-activator targets Yorkie/YAP/TAZ first came to attention because of their role in tissue growth control. Over the past 15 years, it has become clear that, like other developmental pathways (e.g. the Wnt, Hedgehog and TGFβ pathways), Hippo signalling is a 'jack of all trades' that is reiteratively used to mediate a range of cellular decision-making processes from proliferation, death and morphogenesis to cell fate determination. Here, and in the accompanying poster, we briefly outline the core pathway and its regulation, and describe the breadth of its roles in animal development.

Indexed as

Embryonic DevelopmentSignal TransductionAnimalsCell LineageCell PolarityHumansMorphogenesisProtein Serine-Threonine KinasesProtein Serine-Threonine KinasesCell fateDifferentiationGrowthHippo pathwayMorphogenesisYAP

Identifiers

PMID31527062
PMCPMC7100553
OpenAlexW2974552141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.